(Q37523889)

20 August 2017

1 reference

title

Genomic predictors of outcome and treatment response in breast cancer (English)

1 reference

20 August 2017

1 reference

Lara Dunn

1

1 reference

PubMed ID

19537843

20 August 2017

Angela Demichele

series ordinal

2

1 reference

20 August 2017

1 January 2009

1 reference

Molecular Diagnosis and Therapy

20 August 2017

1 reference

20 August 2017

13

1 reference

20 August 2017

73-90

1 reference

20 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256317

20 August 2017

0 references

cites work

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

The Nottingham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

International Agency for Research on Cancer workshop on 'Expression array analyses in breast cancer taxonomy'

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

A gene-expression signature as a predictor of survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Limits of predictive models using microarray data for breast cancer clinical treatment outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

The prognostic role of a gene signature from tumorigenic breast-cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Prospective identification of tumorigenic breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Concordance among gene-expression-based predictors for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Predictors of primary breast cancers responsiveness to preoperative epirubicin/cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Retracted: An Integrated Approach to the Prediction of Chemotherapeutic Response in Patients with Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

Prediction of docetaxel response in human breast cancer by gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256317

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

21 January 2018

1 reference

12 December 2020

Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy

1 reference

12 December 2020

Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer

1 reference

12 December 2020

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

12 December 2020

HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15

1 reference

12 December 2020

Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue

1 reference

12 December 2020

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

1 reference

12 December 2020

Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers

1 reference

12 December 2020

Exploring the two-gene ratio in breast cancer--independent roles for HOXB13 and IL17BR in prediction of clinical outcome

1 reference

12 December 2020

Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer

1 reference

12 December 2020

Immunohistochemical detection of the neu protein in tissue sections of human breast tumors with amplified neu DNA

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256317

1 reference

20 August 2017

1 reference

PubMed ID

19537843